A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Bimagrumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2018 Planned number of patients changed from 60 to 68.